Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsGold Coast Health Plan Prolia Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentGold Coast Health PlanPolicy N/A

    Prolia (denosumab) Coverage Criteria

    Customize your policy alerts

    Sign up for all goldcoasthealthplan policy alerts

    Know when goldcoasthealthplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and Part B coverage for Prolia (denosumab) in eligible Medicare Advantage members. It defines covered osteoporosis uses, required documentation, applicable therapy history, billing information, and the maximum coverage duration.

    Policy Summary
    PayerGold Coast Health Plan
    PolicyProlia (denosumab) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateAug 21, 2025
    Last ReviewAug 21, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing a covered use, prior osteoporosis therapies and treatment responses, and compliance with LCD L34648.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2 yearsMaximum coverage duration
    1 mgJ0897 billing unit
    High fracture riskCovered population
    Prior therapy recordsRequired information

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Covered Uses

    Covered Uses

    Covered when the patient meets at least one covered-use pathway and the request follows applicable LCD requirements.

    Covered use and applicable requirements

    • Covered-use pathways

      • Postmenopausal osteoporosis with high fracture risk

        • High fracture risk definition: The patient has a history of osteoporotic fracture or multiple risk factors for fracture.
      • Failure or intolerance of other therapy: The patient has failed or is intolerant to other available osteoporosis therapy.

        Prior therapies and responses must be documented.

    Billing and Coding

    HCPCSHCPCSCovered
    J0897Prolia (denosumab)

    Authorization and Documentation Requirements

    Prior Authorization

    Part B Prior Authorization Required

    Prior authorization is required for Prolia (denosumab) under Part B. Submit documentation establishing an approved covered use, including the patient’s osteoporosis risk history, prior osteoporosis therapies, and responses to treatment.

    • Covered use: postmenopausal women with osteoporosis at high risk for fracture, defined by a history of osteoporotic fracture or multiple fracture risk factors.
    • Covered use also includes patients who have failed or are intolerant to other available osteoporosis therapy.
    • Submit the request in accordance with applicable Part B requirements and FDA-approved labeling or accepted standards of medical practice.
    Documentation Required

    Document Prior Therapy Failure or Intolerance

    When the request relies on failure or intolerance of other osteoporosis therapy, document the applicable prior treatment history and the clinical basis for failure or intolerance.

    • Identify the prior osteoporosis therapy or therapies used.
    • Describe the treatment response and the reason the therapy was ineffective, not tolerated, or otherwise could not be continued.
    Documentation Required

    Submit Medical Records and Treatment History

    Medical records supporting the request must be submitted. The records must include documentation of prior osteoporosis therapies and the patient’s responses to treatment.

    • Include relevant medical records supporting the diagnosis and request.
    • Document prior therapies and treatment responses.
    • Include clinical information supporting the patient’s fracture risk or failure/intolerance of other available osteoporosis therapy, when applicable.
    Denial Risk

    Covered-Use Criteria Must Be Established

    Coverage may be denied when the request does not establish an approved covered use for Prolia. The submission must demonstrate that the patient meets the applicable clinical criteria.

    • Postmenopausal osteoporosis with high fracture risk must be supported by a history of osteoporotic fracture or multiple fracture risk factors; or
    • Failure or intolerance to other available osteoporosis therapy must be established when that pathway is used.
    Denial Risk

    Missing Records Can Lead to Denial

    A request may be denied or delayed when required medical records, prior osteoporosis therapy information, or treatment responses are missing from the submission.

    • Provide medical records supporting the request.
    • Include prior osteoporosis therapies and documented responses to treatment.
    • Include documentation of failure or intolerance when required to support the covered use.
    Denial Risk

    Follow LCD L34648 Requirements

    Follow LCD L34648, Bisphosphonate Drug Therapy LCD – Bisphosphonate Drug Therapy, as required for coverage. Failure to follow the LCD requirements may result in denial of the request.

    • Applicable LCD: L34648.
    • Ensure the clinical documentation and submission comply with the LCD requirements.

    Prolia Coverage Background

    Prolia (denosumab) is covered for the treatment of postmenopausal women with osteoporosis who are at high risk for fracture. High fracture risk is defined as a history of osteoporotic fracture or multiple risk factors for fracture. Coverage may also apply when a patient has failed or is intolerant to other available osteoporosis therapy.

    Clinical Definitions

    High risk for fracture
    DefinitionHistory of osteoporotic fracture or multiple risk factors for fracture

    Initial Coverage Requirements

    Initial Therapy Criteria

    Initial coverage requires a covered indication, supporting medical records, compliance with LCD L34648, and documentation of prior therapies and responses when applicable.

    Initial Prolia authorization

    • Covered indication: The patient has postmenopausal osteoporosis at high risk for fracture, or has failed or is intolerant to other available osteoporosis therapy.

      High fracture risk means a history of osteoporotic fracture or multiple fracture risk factors.

    • Supporting documentation: Medical records supporting the request document prior therapies and responses to treatment.
    • LCD compliance: The request follows LCD L34648, Bisphosphonate Drug Therapy.

    Prior Osteoporosis Therapy

    StepRequirementDocumentation
    1Patient must have failed or be intolerant to other available osteoporosis therapyDocument prior osteoporosis therapies and responses to treatment in the medical record

    Dose and Duration Limits

    Prolia (denosumab)
    MedicationProlia (denosumab)
    Approval standardFDA-approved labeling or accepted standards of medical practice
    Coverage durationUp to two years
    Policy Summary
    PayerGold Coast Health Plan
    PolicyProlia (denosumab) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateAug 21, 2025
    Last ReviewAug 21, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing a covered use, prior osteoporosis therapies and treatment responses, and compliance with LCD L34648.
    SourceLink
    On This Page
    Covered UsesBilling and CodingAuthorization and Documentation RequirementsProlia Coverage BackgroundClinical DefinitionsInitial Coverage RequirementsPrior Osteoporosis TherapyDose and Duration Limits